Oct. 06, 2021 1:09 PM ETBoston Scientific Corporation (BSX)
By: Dulan Lokuwithana, SA News Editor
Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) has demonstrated superiority over the self-expanding bare metal stents (BMS) in patients with a form of vascular disease, Boston Scientific (NYSE:BSX) says, citing one-year results from its EMINENT trial.
In the trial involving 775 subjects, Eluvia stent has shown ~85% of primary patency rate compared to ~76% for BMS among patients with peripheral artery disease (PAD) and superficial femoral artery (SFA)/ popliteal artery (PPA) lesions (p=0.0077).
Restricting blood flow to limbs, PAD can cause pain in affected individuals. However, a greater portion of patients who were treated with Eluvia stent experienced sustained clinical improvement without interventions (83% for Eluvia compared to ~77% for those treated with BMS at p=0.0450).
Through one year, there were no notable differences in major adverse events or all-cause mortality rates between the two patient groups, the company said.
The data were included in a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
Developed as a treatment for peripheral artery disease, Eluvia stent was granted the FDA approval in 2018.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BSX News
- Boston Scientific Closes Acquisition of Silk Road Medical, Inc. • PR Newswire (US) • 09/17/2024 12:31:00 PM
- Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area • PR Newswire (US) • 09/17/2024 11:00:00 AM
- Boston Scientific Obtains CE Mark for ACURATE Prime™ Aortic Valve System • PR Newswire (US) • 08/27/2024 10:57:00 AM
- Boston Scientific to Participate in Wells Fargo's 2024 Healthcare Conference • PR Newswire (US) • 08/13/2024 12:00:00 PM
- Boston Scientific Elects David Habiger to Board of Directors • PR Newswire (US) • 07/30/2024 08:05:00 PM
- Boston Scientific Announces Results for Second Quarter 2024 • PR Newswire (US) • 07/24/2024 10:30:00 AM
- Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results • PR Newswire (US) • 07/01/2024 12:00:00 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Silk Road Medical, Inc. • PR Newswire (US) • 06/18/2024 05:23:00 PM
- Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc. • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints • PR Newswire (US) • 05/18/2024 03:03:00 PM
- Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors • PR Newswire (US) • 05/08/2024 08:00:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Boston Scientific Announces Results for First Quarter 2024 • PR Newswire (US) • 04/24/2024 10:30:00 AM
- Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module • PR Newswire (US) • 04/08/2024 04:00:00 AM
- Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon • PR Newswire (US) • 03/01/2024 11:55:00 AM
- Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes • PR Newswire (US) • 02/27/2024 09:15:00 PM
- Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes • PR Newswire (US) • 02/23/2024 02:27:00 AM
- Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/05/2024 01:00:00 PM
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023 • PR Newswire (US) • 01/31/2024 11:30:00 AM
- U.S. Futures Waver Ahead of Fed Decision Amid Mixed Corporate Earnings; Oil Prices Slide • IH Market News • 01/31/2024 11:29:30 AM
- Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System • PR Newswire (US) • 01/31/2024 11:25:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc. • PR Newswire (US) • 01/08/2024 09:55:00 PM
- Axonics Shares Climb 20% After Acquisition by Boston Scientific • Dow Jones News • 01/08/2024 04:36:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM